SciClone, Alpha 1 stalemated

SciClone Pharmaceuticals Inc.(SCLN) said it expects to proceed to arbitration with Alpha 1 Biomedicals (ALBM) in a dispute centered on royalty calculations and territorial development issues for Thymosin alpha 1.

Thomas Moore, SCLN chairman and CEO, said SCLN wants to conduct development in the U.S. of an oral formulation of the anti-viral for hepatitis. ALBM objects because the U.S. is not included in the 1991 agreement that granted SCLN the exclusive right to commercialize the drug in all countries except the U.S., Canada, Europe, Israel and Korea. ...